Prevención de cardiotoxicidad con enalapril y carvedilol en cáncer de mama tratadas con antraciclínicos y trastuzumab ION SOLCA 2015 - 2016
Cargando...
Fecha
2017
Autores
Título de la revista
ISSN de la revista
Título del volumen
Editor
Universidad de Guayaquil. Facultad de Ciencias Médicas. Escuela de Graduados
Resumen
Las pacientes que padecen cáncer de mama han aumentado su supervivencia gracias a la
quimioterapia en las cuales utilizan antraciclinas y anticuerpos monoclonales dirigidos contra
los receptores 2 de factor de crecimiento epidérmico humano como el trastuzumab, sin
embargo no se encuentra exento de eventos adversos dentro de ellos la cardiotoxicidad sea de
menor o a largo plazo de forma asintomática o sintomática esta última como la insuficiencia
cardiaca congestiva, sin olvidar que las manifestaciones pueden ser diversas. Su objetivo se
propone estudiar la prevención de cardiotoxicidad con carvedilol y enalapril en pacientes con
cáncer de mama tratadas con antraciclinas y trastuzumab mediante la valoración
ecocardiografica y electrocardiografica y de esta manera demostrar su utilidad. La metodología
del estudio, es cuantitativo correlacional de diseño transversal no experimental. Dentro de los
resultados se demostró que la edad mínima es de 35 años y la máxima de 38 con una media de
50.52 y por medio de la comparación por ecocardiografía se demostró la cardiotoxicidad en
pacientes que recibieron enalapril y carvedilol con un 14.3% (n=2) de 35 pacientes y 20.83%
(n=3) de 24 pacientes respectivamente. vs aquellas pacientes que no recibieron con
disminución de la fracción de eyección en < 55% en un 26% (n= 17) de 61 pacientes, los
cambios electrocardiográficos de control mostró que las pacientes que tomaban enalapril el
14.3% presentaron anormalidades, del grupo de carvedilol fue de 20.83%, en tanto las
pacientes que no recibieron enalapril, carvedilol las anomalías electrocardiográficas fue del
52,5%
Patients suffering from breast cancer have increased their survival through chemotherapy established by the protocols in which they use anthracyclines as well as monoclonal antibodies directed against human epidermal growth factor receptor 2 receptors such as trastuzumab, but are not found Free of adverse events within them, cardiotoxicity is asymptomatic or symptomatic in the short or long term, such as congestive heart failure, without forgetting that the manifestations may be diverse such as arrhythmias, acute coronary syndromes, etc. Its objective is to study the prevention of cardiotoxicity with carvedilol and enalapril in patients with breast cancer treated with anthracyclines and trastuzumab by means of the echocardiographic and electrocardiographic evaluation and thus to prove its usefulness. The methodology of the study, is quantitative correlational non-experimental cross-sectional design. In the results, the echocardiography cardiotoxicity of those patients receiving enalapril and carvedilol was demonstrated by comparison with 14.3% (n = 2) of 35 patients and 20.83% (n = 3) of 24 patients, respectively. Versus those patients who did not receive a reduction of ejection fraction by <55% in 26% (n = 17) of 61 patients, electrocardiographic control changes showed that patients taking enalapril 14.3% had abnormalities in the group Of carvedilol was 20.83%, while the patients who did not receive enalapril, carvedilol electrocardiographic anomalies was 52.5%.
Patients suffering from breast cancer have increased their survival through chemotherapy established by the protocols in which they use anthracyclines as well as monoclonal antibodies directed against human epidermal growth factor receptor 2 receptors such as trastuzumab, but are not found Free of adverse events within them, cardiotoxicity is asymptomatic or symptomatic in the short or long term, such as congestive heart failure, without forgetting that the manifestations may be diverse such as arrhythmias, acute coronary syndromes, etc. Its objective is to study the prevention of cardiotoxicity with carvedilol and enalapril in patients with breast cancer treated with anthracyclines and trastuzumab by means of the echocardiographic and electrocardiographic evaluation and thus to prove its usefulness. The methodology of the study, is quantitative correlational non-experimental cross-sectional design. In the results, the echocardiography cardiotoxicity of those patients receiving enalapril and carvedilol was demonstrated by comparison with 14.3% (n = 2) of 35 patients and 20.83% (n = 3) of 24 patients, respectively. Versus those patients who did not receive a reduction of ejection fraction by <55% in 26% (n = 17) of 61 patients, electrocardiographic control changes showed that patients taking enalapril 14.3% had abnormalities in the group Of carvedilol was 20.83%, while the patients who did not receive enalapril, carvedilol electrocardiographic anomalies was 52.5%.
Descripción
PDF
Palabras clave
Cardiotoxicidad, Neoplasias de la mama, Medicina preventiva, Hospital SOLCA de Guayaquil, Cantón Guayaquil, Ecuador